Safe Harbor StatementStatements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.
www.pharmoscorp.comPHARMOS CORPORATIONCondensed Consolidated Statements of Operations(Unaudited)Three months endedJune 30,Six months endedJune 30,2011201020112010ExpensesResearch and development
$ 214,470$ 103,362$ 496,254$ 226,358General and administrative
259,415300,492553,760639,806Depreciation and amortization
6711851,297650Total operating expenses474,556404,0391,051,311866,814Loss from operations(474,556)(404,039)(1,051,311)(866,814)Other (expense) income Interest income
(25,937)(27,929)(52,406)(56,303)Other income (expense)
-(353)-(869)Other expense(25,877)(27,940)(52,250)(56,543)Net loss$ (500,433)$ (431,979)$ (1,103,561)$ (923,357)Net loss per share- basic and di
|SOURCE Pharmos Corporation|
Copyright©2010 PR Newswire.
All rights reserved